Picture of UK Houses of Parliament

Leading national thinking on politics, government & public policy through Open Access research

Strathprints makes available scholarly Open Access content by researchers in the School of Government & Public Policy, based within the Faculty of Humanities & Social Sciences.

Research here is 1st in Scotland for research intensity and spans a wide range of domains. The Department of Politics demonstrates expertise in understanding parties, elections and public opinion, with additional emphases on political economy, institutions and international relations. This international angle is reflected in the European Policies Research Centre (EPRC) which conducts comparative research on public policy. Meanwhile, the Centre for Energy Policy provides independent expertise on energy, working across multidisciplinary groups to shape policy for a low carbon economy.

Explore the Open Access research of the School of Government & Public Policy. Or explore all of Strathclyde's Open Access research...

An evaluation of minor groove binders as anti-lung cancer therapeutics

Scott, Fraser and Khalaf, Abedawn and Suckling, Colin and Carter, Katharine and Grant, Mary and Henderson, Catherine and Westrop, Gareth and Watson, David (2016) An evaluation of minor groove binders as anti-lung cancer therapeutics. Bioorganic and Medicinal Chemistry Letters. ISSN 0960-894X (In Press)

[img]
Preview
Text (Scott-etal-BMCL2016-an-evaluation-of-minor-groove-binders-as-anti-lung-cancer-therapeutics)
Scott_etal_BMCL2016_an_evaluation_of_minor_groove_binders_as_anti_lung_cancer_therapeutics.pdf
Accepted Author Manuscript

Download (1MB)| Preview

    Abstract

    A series of 47 structurally diverse MGBs, derived from the natural product distamycin, was evaluated for anti-lung cancer activity by screening against the melanoma cancer cell line B16-F10. Five compounds have been found to possess significant activity, more so than a standard therapy, Gemcitabine. Moreover, one compound has been found to have an activity around 70-fold that of Gemcitabine and has a favourable selectivity index of greater than 125. Furthermore, initial studies have revealed this compound to be metabolically stable and thus it represents a lead for further optimisation towards a novel treatment for lung cancer.